Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0S1WV
|
|||
Drug Name |
Enoblituzumab
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 2 | [1] | |
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [2], [3] | ||
Company |
MacroGenics Rockville, MD
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | B7 homolog 3 (CD276) | Target Info | Inhibitor | [2] |
KEGG Pathway | Cell adhesion molecules (CAMs) |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02923180) Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.